The effect of lipopolysaccharide desensitization on the regulation of in vivo induction of immunologic tolerance and antibody production and in vitro release of IL-1.
As previously reported, LPS and 8-derivatized guanosine (both generators of IL-1 release), as well as IL-1 itself interfere with the in vivo induction of tolerance to DHGG in A/J mice. In the present studies it was demonstrated that desensitization of either A/J or CBA/CaJ mice with LPS aborts the ability of LPS to interfere with the induction of tolerance to DHGG. The abrogation of the ability of LPS to interfere with tolerance by LPS desensitization is not the result of neutralization of LPS by antibody produced to LPS during desensitization. Desensitization with LPS also aborts the interference with tolerance induction by 7-methyl-8-oxoguanosine. LPS desensitization inhibits the ability of LPS and/or 7-methyl-8-oxoguanosine to both convert a tolerogenic signal to an immunogenic signal and interfere with the induction of a tolerant state to a subsequent injection of Ag. The effects resulting from desensitization may be in part attributed to the depletion of IL-1. LPS desensitization also modulates the antibody response to injection of the AG, AHGG. Desensitization with LPS markedly suppresses the antibody response to a subsequent injection of AHGG in CBA/CaJ mice. Desensitization with LPS also inhibits the anti-HGG antibody response in A/J mice, but in this strain its effect is dependent on the route of injection of AHGG. In an experiment directly comparing the responses of normal and desensitized A/J mice to either intravenous or intraperitoneal injection of AHGG, desensitization only suppressed the response in mice injected with AHGG i.p.. Desensitization with LPS also inhibits the ability of LPS to act as an adjuvant in a subsequent antibody response to AHGG. Not only does desensitization interfere with the primary antibody response to AHGG, but it also interferes with the secondary response, suggesting that the primary injection after desensitization induces a state of immunologic tolerance.
Weigle
W O
WO
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92937.
Gahring
L C
LC
Romball
C G
CG
Goodman
M G
MG
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D002478:Cells, Cultured; D003888:Desensitization, Immunologic; D007108:Immune Tolerance; D007074:Immunoglobulin G / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007375:Interleukin-1 / Q000096:biosynthesis* / Q000502:physiology; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D051379:Mice; D008805:Mice, Inbred A; D008808:Mice, Inbred CBA; D013045:Species Specificity
D000276:Adjuvants, Immunologic; D000888:Antibodies, Anti-Idiotypic; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D008070:Lipopolysaccharides